Kyorin Pharmaceutical is actively engaged in drug discovery and development, focusing on creating high-value new drugs that address unmet medical needs. The company employs a multifaceted approach to drug discovery, integrating traditional small molecule techniques with innovative modalities such as nucleic acid drug discovery. This strategy is part of their medium-term business plan, "Vision 110 –Stage1–," which emphasizes collaboration with external organizations and the incorporation of advanced technologies to enhance their research capabilities. Kyorin is particularly focused on diseases like fibrosis and immune disorders, aiming to leverage both internal expertise and external partnerships to drive innovation in drug development.

In addition to its research initiatives, Kyorin Pharmaceutical is committed to maintaining high manufacturing standards and optimizing production processes. The company operates three production facilities, each designed to ensure a stable supply of high-quality products while adhering to stringent Good Manufacturing Practices (GMP). Kyorin's manufacturing strategy includes the construction of a new plant in Takaoka City, which will enhance their capacity for producing oral solid formulations and improve overall manufacturing efficiency. By focusing on cost reduction and quality assurance, Kyorin aims to strengthen its competitive position in the pharmaceutical market while addressing the evolving demands of healthcare.

Japan

Kyorin group is working to realize it corporate philosophy “Kyorin continues to fulfill its mission of cherishing life and benefiting society by contribution to better health.” This content provides the history of KYORIN Group.

Kyorin Pharmaceutical

Company Details